ClinicalTrialsFinder
RecruitingNCT05989620

Long-Term Development of Muscular Dystrophy Outcome Assessments

Long-Term Development of Muscular Dystrophy Outcome Assessments (GRASP-01-005)

Sponsor

Virginia Commonwealth University

Enrollment

1,000 participants

Start Date

Oct 18, 2023

Study Type

OBSERVATIONAL

Conditions

LGMD1BLGMD1CLGMD1DLGMD1ELGMD1FLGMD1GLGMD1HLGMD2ALGMD2BLGMD2CLGMD2DLGMD2ELGMD2FLGMD2GLGMD2ILGMD2JLGMD2KLGMD2LLGMD2MLGMD2NLGMD2OLGMD2PLGMD2QLGMD2SLGMD2TLGMD2ULGMD2WLGMD2XLGMD2Y

Summary

This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).

Eligibility

Min Age: 6 YearsMax Age: 50 Years

Inclusion Criteria4

  • Age between 6-50 years at enrollment
  • Clinically affected (defined as weakness on bedside evaluation in a pattern consistent with proximal weakness)
  • Genetic confirmation of a LGMD, DM2, or LOPD
  • FVC above 30% of predicted

Exclusion Criteria2

  • Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator
  • Participation in a clinical trial receiving an investigational product
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05989620

Related Trials

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

NCT052304596 locations

LGMD R1 Natural History Study

NCT0561808012 locations